Crom W R
Pharmaceutical Division, St. Jude Children's Research Hospital, Memphis, TN 38105.
Am J Hosp Pharm. 1992 Sep;49(9 Suppl 1):S9-14.
The clinical importance of individual pharmacokinetic and pharmacodynamic differences among enantiomers is discussed. A number of mechanisms in the body can be stereoselective, among them first-pass metabolism, metabolic clearance, renal clearance, and protein and tissue binding. Differences in first-pass metabolism may cause differences in the ratio of plasma concentrations of enantiomers when a drug is given by the intravenous route compared with the oral route. Stereoisomers of a drug may be metabolized by two different enzyme systems, resulting in different rates of metabolic clearance; age and sex may also affect the rates of enzymatic metabolism of stereoisomers. Substantial differences in the protein binding of two enantiomers may result in a difference in their glomerular filtration rates. Two enantiomers may bind differently to protein or to other tissue receptor sites, resulting in differences in drug effects or distribution. There are no simple answers to questions regarding the pharmacokinetics of racemic drug mixtures and single enantiomers. The properties of enantiomers in each drug will have to be evaluated for their pharmacokinetic disposition and their therapeutic index.
本文讨论了对映体之间个体药代动力学和药效学差异的临床重要性。体内的许多机制可能具有立体选择性,其中包括首过代谢、代谢清除、肾清除以及蛋白质和组织结合。当药物通过静脉途径给药与口服途径给药相比时,首过代谢的差异可能导致对映体血浆浓度比值的差异。药物的立体异构体可能由两种不同的酶系统代谢,从而导致代谢清除率不同;年龄和性别也可能影响立体异构体的酶促代谢速率。两种对映体在蛋白质结合方面的显著差异可能导致它们的肾小球滤过率不同。两种对映体可能与蛋白质或其他组织受体位点的结合方式不同,从而导致药物效应或分布的差异。关于外消旋药物混合物和单一异构体的药代动力学问题没有简单的答案。每种药物中对映体的性质必须根据其药代动力学处置和治疗指数进行评估。